NCT02048943View on ClinicalTrials.gov

Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2015

Primary Completion Date

November 30, 2015

Conditions
Duct Cell Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

dovitinib lactate

Given PO

DRUG

gemcitabine hydrochloride

Given IV

DRUG

paclitaxel albumin-stabilized nanoparticle formulation

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Novartis

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER